Ixekizumab

(Taltz®)

Ixekizumab

Latest News

loading GIF

Drug updated on 4/26/2024

Dosage FormInjection (subcutaneous; 80 mg/mL)
Drug ClassHumanized interleukin-17A antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  • Indicated for the treatment of adults with active psoriatic arthritis.
  • Indicated for the treatment of adults with active ankylosing spondylitis.
  • Indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ixekizumab (Taltz) is indicated for the treatment of patients aged 6 years or older with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis. It has demonstrated superior effectiveness in achieving complete resolution of nail psoriasis over adalimumab and other treatments.
  • A total of 35 systematic reviews/meta-analyses were reviewed to gather information about Taltz's efficacy and safety compared to other drugs.
  • In treating axial spondyloarthritis (axSpA), Ixekizumab showed significant improvements in ASAS40, ASDAS, and SPRACC scores compared to placebo but was associated with an increased risk of non-serious adverse events.
  • For non-radiographic spondyloarthritis (nr-axSpA), certolizumab pegol showed higher efficacy than ixekizumab in specific outcomes, indicating preference in certain patient subgroups.
  • When used for psoriasis (PSO), Ixekizumab ranked among the top treatments for achieving PASI 90 short-term results, closely following or surpassing other IL-17 and IL-23 inhibitors' efficacy levels.
  • The safety profile of Ixekizumab was comparable to a placebo concerning serious adverse events but had a significant increase in nonserious adverse events when used for axSpA. Across multiple studies, its safety profile remained consistent, showing most prevalent but manageable concerns such as infections and injection site reactions.
  • Among pediatric patients suffering from moderate-to-severe psoriasis, ixekizumab demonstrated high efficiency along with favorable side effects, making it a suitable choice within this population group.
  • The efficacy level between Caucasians and Asians did not significantly differ while using IL-17 inhibitors like ixekizumab for treating psoriasis, suggesting its broad applicability across these ethnic groups.

Product Monograph / Prescribing Information

Document TitleYearSource
Taltz (ixekizumab) prescribing information.2022Eli Lilly and Company, Indianapolis, IN

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis.2023Clinical and Experimental Dermatology
The efficacy and safety of subcutaneous ixekizumab for the treatment of axial spondylarthritis: a systematic review and meta-analysis.2023Cureus
Comparative efficacy of biologic disease-modifying anti-rheumatic drugs for non-radiographic axial spondyloarthritis: a systematic literature review and bucher indirect comparisons2023Rheumatology and Therapy
The effectiveness of anti-interleukin-17A treatment for pityriasis rubra pilaris: a systematic review. 2023Cureus
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2023The Cochrane Database of Systematic Reviews
Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis.2022Dermatology and Therapy
Biologics for pediatric psoriasis: a systematic review and meta-analysis.2022Pediatric Dermatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis.2022The Cochrane Database of Systematic Reviews
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. 2022RMD Open
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. 2022Journal of Dermatological Treatment
Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between Caucasians and Asians: a systematic review and meta-analysis. 2022Frontiers in Medicine
Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis.2022Pharmaceutics
Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.2022Journal of the German Society of Dermatology
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. 2021Dermatology Therapy
Model-based meta-analysis in psoriasis: a quantitative comparison of biologics and small targeted molecules. 2021Frontiers in Pharmacology
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: a combined and updated meta-analysis.2021Journal of Clinical Pharmacy and Therapeutics
Meta-analysis and indirect comparisons: on methods, paradigms, and biologic treatments for psoriasis. 2021Actas Dermo-Sifiliográficas (English Edition)
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. 2021Journal of the European Academy of Dermatology and Venereology
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. 2021Clinical Rheumatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. 2021The Cochrane Database of Systematic Reviews
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. 2021Journal of the German Society of Dermatology
Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis.2021Journal of Rheumatology
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials.2021Clinical Rheumatology
Short-term efficacy of biologic therapies in moderate-to-severe plaque psoriasis: a systematic literature review and an enhanced multinomial network meta-analysis.2021Dermatology Therapy
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.2021Journal of Dermatological Treatment
Adverse events with IL‐17 and IL‐23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta‐analysis of phase III studies.2020Journal of the European Academy of Dermatology and Venereology
Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis2020JAMA Dermatology
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.2020Rheumatic & Musculoskeletal Diseases
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.2020Journal of the European Academy of Dermatology and Venereology
Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis.2020Arthritis Research and Therapy
Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting jak and pde4 in the treatment of nail psoriasis: a network meta-analysis.2020Acta Dermato-Venereologica
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: a network meta-analysis.2019Journal of Pharmacological Sciences
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis.2019Seminars in Arthritis and Rheumatism
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019PLoS One
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology

Clinical Practice Guidelines